Has the South Korean Healthtech Industry valuation changed over the past few years?

Investors are pessimistic on the South Korean Healthcare Services industry, indicating that they anticipate long term growth rates will be lower than they have historically. The 3-year average PS ratio of 6.1x is higher than the industry's current PS ratio of 4.2x.

Which industries have driven the changes within the South Korean Healthcare industry?

There are no additional sub-industries under this industry.

South Korean (KOSPI) Healthtech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 06 Jul 2026	₩3.1t	₩738.0b	-₩40,896,938,140.00	8.5x	-75.4x	4.2x
Wed, 03 Jun 2026	₩3.7t	₩728.9b	-₩43,937,727,780.00	8.9x	-83.5x	5x
Fri, 01 May 2026	₩4.6t	₩691.1b	-₩52,604,422,500.00	9.2x	-87.2x	6.6x
Sun, 29 Mar 2026	₩4.6t	₩690.9b	-₩28,943,501,260.00	8.5x	-159.9x	6.7x
Tue, 24 Feb 2026	₩2.8t	₩590.6b	-₩69,408,221,100.00	8.7x	-40.7x	4.8x
Thu, 22 Jan 2026	₩2.5t	₩590.6b	-₩69,408,221,100.00	7.4x	-35.4x	4.2x
Sat, 20 Dec 2025	₩2.6t	₩590.6b	-₩69,408,221,100.00	7.7x	-37.1x	4.4x
Mon, 17 Nov 2025	₩2.5t	₩590.6b	-₩87,802,455,910.00	8.9x	-28.1x	4.2x
Wed, 15 Oct 2025	₩2.5t	₩587.8b	-₩117,710,536,000.00	9.3x	-21.3x	4.3x
Fri, 12 Sep 2025	₩2.7t	₩587.8b	-₩117,710,536,000.00	11.5x	-22.7x	4.5x
Sun, 10 Aug 2025	₩3.3t	₩581.6b	-₩119,895,420,550.00	33.6x	-27.2x	5.6x
Tue, 08 Jul 2025	₩3.1t	₩581.6b	-₩119,895,420,550.00	27.9x	-25.6x	5.3x
Thu, 05 Jun 2025	₩3.0t	₩583.2b	-₩118,503,378,990.00	23.4x	-25.3x	5.2x
Sat, 03 May 2025	₩3.1t	₩563.2b	-₩137,189,191,030.00	10.3x	-22.8x	5.5x
Mon, 31 Mar 2025	₩3.0t	₩563.2b	-₩137,189,191,030.00	9.3x	-21.8x	5.3x
Wed, 26 Feb 2025	₩3.3t	₩553.0b	-₩144,988,211,610.00	10.8x	-22.8x	6x
Fri, 24 Jan 2025	₩3.3t	₩536.1b	-₩85,171,350,030.00	10.7x	-39.1x	6.2x
Sun, 22 Dec 2024	₩3.0t	₩536.1b	-₩85,171,350,030.00	11.1x	-35.5x	5.6x
Tue, 19 Nov 2024	₩2.9t	₩513.2b	-₩83,016,859,320.00	12.6x	-35.3x	5.7x
Thu, 17 Oct 2024	₩2.5t	₩504.1b	-₩85,882,642,230.00	13.2x	-29x	4.9x
Sat, 14 Sep 2024	₩2.4t	₩504.1b	-₩85,882,642,230.00	13.3x	-27.7x	4.7x
Mon, 12 Aug 2024	₩2.3t	₩479.3b	-₩114,966,911,080.00	16.5x	-19.6x	4.7x
Wed, 10 Jul 2024	₩2.8t	₩479.3b	-₩114,966,911,080.00	17.6x	-24.6x	5.9x
Fri, 07 Jun 2024	₩3.1t	₩480.1b	-₩121,015,467,340.00	11.7x	-25.7x	6.5x
Sun, 05 May 2024	₩3.1t	₩472.9b	-₩116,225,868,680.00	12.2x	-27x	6.6x
Tue, 02 Apr 2024	₩3.4t	₩472.9b	-₩116,225,868,680.00	13.2x	-29.7x	7.3x
Thu, 29 Feb 2024	₩3.6t	₩466.9b	-₩121,958,864,840.00	16.4x	-29.4x	7.7x
Sat, 27 Jan 2024	₩3.8t	₩470.3b	-₩126,434,108,550.00	14.9x	-30.2x	8.1x
Mon, 25 Dec 2023	₩4.4t	₩473.1b	-₩129,782,846,150.00	14.1x	-33.6x	9.2x
Wed, 22 Nov 2023	₩4.2t	₩473.0b	-₩129,648,870,530.00	16.5x	-32.2x	8.8x
Fri, 20 Oct 2023	₩3.2t	₩472.1b	-₩129,827,783,480.00	15.2x	-24.9x	6.8x
Sun, 17 Sep 2023	₩4.7t	₩468.0b	-₩119,615,334,030.00	17.7x	-39.6x	10.1x
Tue, 15 Aug 2023	₩3.9t	₩460.8b	-₩96,255,067,860.00	17.2x	-40.7x	8.5x
Thu, 13 Jul 2023	₩3.8t	₩460.8b	-₩96,255,067,860.00	19x	-39x	8.2x


KR Market	-3.59%
Healthcare	5.52%
Healthtech	21.08%
Healthtech	21.08%

Company	Last Price	7D	1Y	Valuation
A347700 Sphere	₩24.50k	20.4% +₩198.4b	146.5%	PE27.2x
A263700 CarelabsLtd	₩2.28k	10.1% +₩4.1b	-40.0%	PS0.6x
A071200 INFINITT Healthcare	₩6.78k	2.1% +₩3.4b	2.0%	PE4.1x
A032850 BIT Computer	₩4.15k	2.3% +₩1.5b	-20.7%	PE8.5x
A226330 SyntekaBio	₩1.62k	0.7% +₩266.8m	-76.5%	PS13.2x

Announcement • May 24

Lunit Presents Ai-Powered Ihc Biomarker Quantification and Spatial Tumor Microenvironment Analysis At Asco 2026

Lunit announced that five studies featuring its AI biomarker platforms are being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago, IL. This year's presentations reflect Lunit's expanding biomarker research beyond conventional immune profiling toward integrated AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment (TME) analysis. Using AI to characterize HER2 expression, immune phenotypes, tertiary lymphoid structures (TLS), tumor-infiltrating lymphocytes (TILs), and endothelial cells, the studies highlight the potential of integrated biomarker analysis to improve precision patient stratification across multiple cancer types. The five presentations include studies across biliary tract cancer (BTC), non-small cell lung cancer (NSCLC), adenoid cystic carcinoma (ACC), microsatellite-stable (MSS), metastatic colorectal cancer and advanced gastric cancer (AGC). One of the featured studies, led by researchers at Yonsei University College of Medicine, evaluates a first-line quadruplet regimen consisting of trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive advanced BTC. Using AI-powered whole-slide image (WSI) analysis, researchers analyze HER2 expression and immune phenotypes within tumor tissue. Among 40 patients enrolled in the multi-center phase Ib/II trial, the combination of therapy demonstrates an objective response rate (ORR) of 55%, disease control rate (DCR) of 95%, and median progression-free survival (PFS) of 10.6 months. Patients with HER2 IHC 3+ tumor cell proportions =10%, as identified by AI analysis, achieve substantially higher response rates compared to those below the threshold (80% vs. 36.4%). The study demonstrates how integrated AI-powered HER2 and spatial tumor microenvironment analysis may help identify patients more likely to benefit from HER2-targeted combination therapies. Another study characterizes the tumor microenvironment landscape of HER2-overexpressing NSCLC using AI-powered spatial analysis. Across more than 2,000 NSCLC whole-slide images, HER2-overexpressing tumors demonstrate significantly reduced tumor-infiltrating lymphocyte density and lower proportions of inflamed immune phenotype compared to non-overexpressing tumors. The immune-cold phenotype becomes more pronounced in tumors with higher proportions of HER2 3+ cells. The study provides additional insight into the biological relationship between HER2 overexpression and tumor immune status, while highlighting the broader potential of combining AI-powered HER2 analysis with spatial tumor microenvironment characterization in biomarker research. Another featured study, conducted with Seoul National University Hospital, explores AI-powered spatial tumor microenvironment analysis in adenoid cystic carcinoma (ACC), a rare cancer with limited treatment options. Researchers identify a subgroup of ACC patients with high endothelial cell and tumor-infiltrating lymphocyte (TIL) densities who demonstrate significantly prolonged progression-free survival following axitinib treatment (19.6 months vs. 11.1 months). The findings suggest that AI-based spatial profiling may help distinguish responder populations that are difficult to stratify using conventional biomarkers alone. Researchers at Asan Medical Center investigate AI-powered tumor microenvironment analysis in MSS metastatic colorectal cancer, which is generally considered resistant to immune checkpoint inhibitors (ICIs). Researchers find that patients with larger tertiary lymphoid structure (TLS) regions identified by AI demonstrate improved progression-free survival and overall survival following immunotherapy. The findings highlight the potential of AI-powered spatial analysis to identify MSS colorectal cancer patients more likely to benefit from immunotherapy.

South Korean (KOSPI) Healthtech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New minor risk - Dividend sustainability

Investors Shouldn't Be Too Comfortable With ezCaretech's (KOSDAQ:099750) Earnings

New minor risk - Market cap size

Investor sentiment improves as stock rises 21%

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Lunit Presents Ai-Powered Ihc Biomarker Quantification and Spatial Tumor Microenvironment Analysis At Asco 2026

New minor risk - Market cap size

Investor sentiment improves as stock rises 20%

New major risk - Financial position

Full year 2025 earnings released: ₩1,837 loss per share (vs ₩3,541 loss in FY 2024)

Full year 2025 earnings released: EPS: ₩471 (vs ₩479 in FY 2024)

Coreline Soft Co., Ltd., Annual General Meeting, Mar 27, 2026